Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin

Melanoma Research

Volumn 13, Issue 5, 2003, Pages 493-501

  Giatromanolaki, Alexandra ^a,d   Sivridis, Efthimios ^a   Kouskoukis, Constantinos ^a   Gatter, Kevin C ^b,c   Harris, Adrian L ^b,c   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d Tumor and Angiogenesis Research Group Alexandroupolis   (Greece)

Author keywords

Hypoxia inducible factors; Melanoma; Thymidine phosphorylase; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; THYMIDINE PHOSPHORYLASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CELL INFILTRATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; EPITHELIOID CELL; EXCISION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INFLAMMATORY CELL; MALE; MELANOMA; MITOSIS RATE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME; ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, CD31; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL NUCLEUS; CYTOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SKIN NEOPLASMS; THYMIDINE PHOSPHORYLASE; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0142120661     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200310000-00008     Document Type: Article

References (37)

1. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 1999; 135:275-280.
2. Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000; 88:1063-1071.
3. Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer 2002; 38:511-516.
4. Balch CM, Eggermont AMM, Kirkwood JM, Rosengerg SA. Adjuvant therapy for melanoma. In: Perry MC (editor): American Society of Clinical Oncology 2001 Educational Book. Alexandria: American Society of Clinical Oncology; 2001, pp. 81-104.
5. Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159:223-235.
6. Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K, Pyrhonen S. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999; 9:59-68.
7. Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/ EphA2 on melanoma progression. Am J Pathol 2002; 160: 1009-1019.
8. Moghaddam A, Zhang HT, Fan TPD, Hu DE, Lees VC, Turley H, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92:998-1002.
9. Brown JM. The hypoxic cell: a target for selective cancer therapy -eighteenth Bruce F. Cain memorial award lecture. Cancer Res 1999; 59:5863-5870.
10. Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 2002; 62:1847-1853.
11. Kunz M, Hartmann A, Flory E, Toksoy A, Koczan D, Thiesen HJ, et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol 1999; 155:753-763.
12. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13:167-171.
13. 2-dependent degradation domain via the ubiquitine-proteasome pathway. Proc Natl Acad Sci USA 1998; 95:7987-7992.
14. Vucovic V, Haugland HK, Nicklee T, Morrison AJ, Medley DW. Hypoxia-inducible factor-1 alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001; 61:7394-7398.
15. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85:881-890.
16. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PAE et al. Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998; 4:3017-3024.
17. Koukourakis MI, Giatromanolaki A, O'Byrne K, Comley M, Whitehouse R, Talbot DC, et al. Platelet-derived endothelial cell growth factor expression correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Br J Cancer 1997; 4:477-481.
18. Giatromanolaki A, Koukourakis M, Theodossiou D, Barbatis C, Harris AL, Gatter KC. Comparative evaluation of angiogenesis assessment with anti-factor VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 1997; 3:2493-2500.
19. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
20. Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002; 86:301-308.
21. Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br J Cancer 2000; 82:1528-1534.
22. Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998; 77:1799-1805.
23. Chapman JD. Measurment of tumour hypoxia by invasive and non-invasive procedures: a review of the recent clinical studies. Radiother Oncol 1991; 20:13-19.
24. 31P magnetic resonance spectroscopy: an experimental study of human melanoma xenografts. Radiother Oncol 1999; 52: 261-267.
25. Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2′ -(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res 2000; 60: 4582-4588.
26. Lartigau E, Randrianarivelo H, Avril MF, Margulis A, Spatz A, Eschwege F, Guichard M. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res 1997; 7:400-406.
27. Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs 2000; 9: 2889-2901.
28. Zhang M, Stevens G. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines. Melanoma Res 1998; 8:510-515.
29. Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res 1998; 152:341-352.
30. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53:1192-1202.
31. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI. Association of hypoxia-inducible factors 1 alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002; 95:1055-1063.
32. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 1998; 92:2260-2268.
33. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002; 62:1326-1329.
34. Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, et al. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 2002; 8:471-480.
35. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002; 16:1453-1455.
36. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94:4273-4278.
37. Kung AL, Wang S, Kico JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000; 6:1335-1340.